Sabine Kahl completed her medical training at Saarland University, Homburg/Saar, Germany in 2008. In parallel, she performed her doctoral training at the Institute of Clinical and Experimental Pharmacology of Saarland University, exploring the L-type calcium channel β2 proteins and their influence on calcium current in murine heart, graduating with distinction in 2009. She continued her career at the Medical Faculty and University Hospital of Düsseldorf as well as at the Institute for Clinical Diabetology at the German Diabetes Center, Düsseldorf and joined the research group ‘Energy Metabolism’ led by Professor Michael Roden in 2016. She is currently the deputy head of the group.
In 2020, Dr Kahl completed her board certification in clinical pharmacology. Her research interests include the pathogenesis, diagnosis and treatment of type 2 diabetes and its concomitant diseases, with particular focus on non-alcoholic fatty liver disease (NAFLD). She has authored more than 20 publications in international journals and has received a number of awards for her work. Dr Kahl teaches medical students at the Heinrich-Heine-University Düsseldorf in the area of diabetes and comorbidities and also supervises medical doctoral theses.